Molecular alterations for prognosis of malignant gliomas
Are there any molecular alterations that are useful in the prognosis of malignant gliomas?
Tumors with methyl guanine methyl transferase (MGMT) promoter methylation and mutations in the enzymes isocitrate dehydrogenase-1 (IDH1) and IDH2 have improved prognosis in malignant gliomas.
Additionally, glioblastoma studies show MGMT may be predictive of response to temozolomide therapy as MGMT methylation silences an enzyme responsible for DNA repair following alkylating agent chemotherapy.
Combined loss of genetic materials from chromosomes 1p and 19q is a major prognostic and predictive factor for improved survival and response to therapy in oligodendroglioma.
